Please assess the completion status of the following clinical trial:

Trial Title: Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pseudophakic or phakic and scheduled for a cataract operation~* Macular oedema due to DME~Exclusion Criteria:~* Previous Ozurdex® treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ozurdex® (dexamethasone intravitreal implant) (Type: None): Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).